biocartis 品牌介绍
品牌简介
Biocartis是一家创新的分子诊断公司，致力于通过其独特的专有IdyllaTM平台彻底改变分子测试。我们提供下一代诊断解决方案，旨在改善临床实践，造福于患者、临床医生、付款人和医疗保健行业，重点关注代表全球MDx市场增长最快部分的肿瘤学。如今，Biocartis提供支持黑色素瘤、结直肠癌和肺癌的检测，以及SARS-CoV-2和败血症的检测。 Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as tests for SARS-CoV-2 and sepsis. Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring. Biocartis employs approx. 500 people and is headquartered in Mechelen, Belgium. dyllaTM Platform IdyllaTM Oncology Assays IdyllaTM Infectious Disease Assays https://www.biocartis.com
Biocartis的专有分子诊断（MDx）IdyllaTM平台是一个完全自动化的样本到结果实时PCR系统，它在几乎任何环境下从几乎任何生物样本中提供准确、高度可靠的分子信息，允许快速有效的治疗选择和治疗进展监测。
Biocartis拥有约500名员工，总部位于比利时梅切伦。
联系我们
